



U.S. melanoma demographics

- Sixth most common new cancer diagnosis
- In 2009, ~70,000 new cases and ~9,000 deaths
- Most common cancer in women age 25-29
- 5-year survival <15% for patients with stage IV metastatic disease
- **Only three** FDA-approved agents for prevention or treatment of metastatic disease (interferon alpha, dacarbazine, interleukin-2)


Incidence is rising



Targeted melanoma therapy: a KIT-activating mutation predicts major response to imatinib



Curtin JA et al, *J Clin Oncol* 2006;
Hodi FS et al, *J Clin Oncol* 2008




Melanoma immunotherapy: Animal models inform clinical development of immunomodulatory antibodies

Pre-treatment




Post-treatment



Anti-CTLA-4, anti-PD-1, anti-B7-H1, and others.

FDA Modernization Project





Prostate
Cancer
Foundation

Incalculable

Social Capital


\$100 billion

Human Capital

\$10 billion

Financial Capital

\$400M



A New Generation of Young Investigators

